Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- CNTB
- Price
- 0.60
- Stock movement down
- -0.00 (-0.02%)
- Company name
- Connect Biopharma Holdings Ltd
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 33.15M
- Ent value
- -66.93M
- Price/Sales
- 1.37
- Price/Book
- 0.30
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- 4.34
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -71.96%
- 3 year return
- -41.84%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-08
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
CNTB does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 4.34 |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | 4.06 |
| EV to EBITDA | -8.20 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 1.37 |
| Price to Book | 0.30 |
| EV to Sales | -2.78 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 55.25M |
| EPS (TTM) | 0.14 |
| FCF per share (TTM) | -0.08 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 24.12M |
| Gross profit (TTM) | 24.12M |
| Operating income (TTM) | 7.29M |
| Net income (TTM) | 7.63M |
| EPS (TTM) | 0.14 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | 100.00% |
| Operating margin (TTM) | 30.23% |
| Profit margin (TTM) | 31.65% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 110.17M |
| Net receivables | 3.56M |
| Total current assets | 115.90M |
| Goodwill | 0.00 |
| Intangible assets | 57.00K |
| Property, plant and equipment | 0.00 |
| Total assets | 120.57M |
| Accounts payable | 5.70M |
| Short/Current long term debt | 325.00K |
| Total current liabilities | 9.62M |
| Total liabilities | 10.09M |
| Shareholder's equity | 110.48M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -7.98M |
| Capital expenditures (TTM) | 436.01K |
| Free cash flow (TTM) | -4.22M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 6.91% |
| Return on Assets | 6.33% |
| Return on Invested Capital | 6.89% |
| Cash Return on Invested Capital | -3.81% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.60 |
| Daily high | 0.66 |
| Daily low | 0.60 |
| Daily Volume | 64K |
| All-time high | 28.50 |
| 1y analyst estimate | 7.00 |
| Beta | -0.31 |
| EPS (TTM) | 0.14 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| CNTB | S&P500 | |
| Current price drop from All-time high | -97.89% | -19.00% |
| Highest price drop | -98.07% | -56.47% |
| Date of highest drop | 31 Mar 2025 | 9 Mar 2009 |
| Avg drop from high | -82.03% | -11.07% |
| Avg time to new high | 60 days | 12 days |
| Max time to new high | 920 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
33.15M
Marketcap category
Small-cap
Description
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.
Employees
81
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page